All Themes

ACO economics are becoming more platform-driven and risk-analytics-intensive: conveners and enablement companies are increasingly shaping MSSP participation “behind the scenes,” while vendors such as Arbital are building tools to model downside risk under CMS’s LEAD ACO program—signaling that capital, data infrastructure, and actuarial sophistication are becoming prerequisites for provider groups moving deeper into value-based care ([Health Affairs on ACO conveners](https://news.google.com/rss/articles/CBMickFVX3lxTE5hZU1JTDFjel9OdkoyaEF0RGNtUFhqMVdwUTdEbGQzc0ZaTV9fRUxLS3M4ampDVzV3bjVZNHpUWl9MTmNkaktzY1VyWnUya2xRdFc1cS1DSHloazNnM0tpY1E3SmtvdzRMV3EzQlRiSGJMUQ?oc=5)). At the same time, reported shared-savings results from Astrana Health and agilon health show that scaled primary-care enablement models can still generate meaningful Medicare savings, but the Trump administration’s finalized 2.48% Medicare Advantage payment hike for 2027 keeps MA benchmarks, coding intensity, and payer-provider risk contracting central to VBC strategy. For health systems, ACO leaders, and payers, the near-term positioning question is whether to build or partner for enablement capabilities—risk analytics, contracting, care management, and capital access—needed to succeed in both MSSP and Medicare Advantage risk arrangements.

Medicare Advantage affordability scrutiny is intensifying as rising federal spend, coding/bonus concerns, and plan economics converge: KFF-linked reporting shows MA quality bonus payments are expected to exceed $13B in 2026 despite fewer members in bonus-eligible plans, while policy proposals such as the Saving MEDICARE Act aim to reduce MA overpayments and tighten payment integrity ([MA bonuses exceed $13B](https://www.healthcaredive.com/news/medicare-advantage-bonus-program-spend-13-billion-this-year-kff/824311/)). For VBC stakeholders, the strategic tension is shifting from “MA as growth engine” to “MA as affordability target,” with payers defending medical cost control, policymakers questioning whether MA has delivered savings, and providers needing to prepare for tougher risk adjustment, quality, and contract economics. At the same time, home-based providers such as Bayada are moving beyond payer contracts toward deeper value-based risk arrangements, signaling that care delivery organizations still see population health and total-cost accountability as scalable—if they can manage downside risk in a more fiscally constrained MA environment ([Bayada value-based risk strategy](https://homehealthcarenews.com/2026/07/beyond-payer-contracts-how-bayadas-new-ceo-plans-to-scale-through-value-based-risk/)).

CMS’s latest ACO REACH results strengthen the case for keeping or replacing advanced two-sided-risk population models: the soon-to-sunset model generated $988 million in Medicare savings in 2024, while participants such as agilon reported material gross savings and Medicare Trust Fund savings, sharpening the tension between model termination and the Trump administration’s broader push to expand accountable care ([ACO REACH savings](https://www.healthcaredive.com/news/aco-reach-generates-more-savings-medicare/824965/)). At the same time, CMS is positioning MSSP and new pathways such as LEAD as the main vehicles for Medicare VBC scale, with organizations now weighing LEAD versus MSSP participation amid unresolved financial methodology details, while proposed physician payment reforms would phase out MIPS and further steer clinicians toward ACO participation ([LEAD risk mitigation](https://www.wakely.com/blog/accepted-into-lead-now-what-aco-risk-mitigation-strategies-part-2/)). For health systems, ACOs, and payers, the strategic priority is shifting from “whether to enter risk” to portfolio design—choosing between MSSP, LEAD, successor ACO REACH-like models, bundled payment extensions such as CJR-X, and MA risk-adjustment exposure as CMS tightens expectations around savings, coding accuracy, governance, and downside-risk readiness.

Care coordination is becoming the operational hinge of VBC strategy as CMS models and private-risk arrangements increasingly reward specialty integration, post-acute visibility, and scalable patient outreach rather than isolated primary-care attribution. The July launch of the CMS ACCESS Model is drawing attention to whether digital chronic-care vendors can make Medicare economics work at lower annual payment levels, while ACO REACH savings claims from NAACOS reinforce the strategic value of care-delivery infrastructure that can manage complex beneficiaries across settings ([AMA on CMS ACCESS](https://news.google.com/rss/articles/CBMiwgFBVV95cUxPdm0wY1I3d0IyR1UycEIxeGZZcWtaaDdrWDZpUEVXYVlWbHhSeHF2N20zRUNkU1pkTUE2NmtuV0p3TWtnUWl6cHJOOVM4elIwckZkQ0U2OWJiWklTTDVRbDFldTNDdkRKcjV3QmpQRWxHcFJEdllxbEpwdEhIdTJROVdCVVJCSWxWbnpSQW4xUVk3Y3R6RGs1a1dESTdZSjZiUWVKcVZudnppOUE2dDdWTkpKRnk2UmlPWGdxYVlVdEE5Zw?oc=5)). At the same

CMS is signaling a more aggressive Medicare payment-policy pivot toward accountable care: ACO REACH produced $988 million in Medicare savings in 2024 before its scheduled sunset, while organizations are weighing LEAD versus MSSP participation as CMS prepares financial-methodology details and proposed physician payment reforms that would expand ACO participation and move away from MIPS. The strategic tension for VBC stakeholders is whether the Trump administration under CMS Administrator Dr. Mehmet Oz and CMMI Director Abe Sutton will preserve REACH-like risk arrangements through LEAD/MSSP redesign or replace them with tighter guardrails, especially as Medicare Advantage coding intensity and CMMI Trust Fund payment transparency remain under scrutiny. For ACOs, physician groups, and payers, the near-term priority is positioning around downside-risk readiness, participant TIN strategy, benchmark exposure, and model optionality before final CMS rules and LEAD decisions land ([ACO REACH savings](https://www.healthcaredive.com/news/aco-reach-generates-more-savings-medicare/824965/); [LEAD risk mitigation](https://www.wakely.com/blog/accepted-into-lead-now-what-aco-risk-mitigation-strategies-part-2/)).

CMS is moving to rewire Medicare quality and value-based payment architecture by proposing physician payment reforms that would phase out MIPS, expand ACO participation, and recalibrate incentives toward primary care and accountable care—while provider groups weigh the upside of VBC simplification against a proposed 2027 physician fee cut. At the same time, Congress is advancing relief from ACO quality reporting burden, and Medicare Advantage stakeholders are bracing for continued scrutiny of Stars/QBP economics as MA quality bonuses are projected to exceed $13 billion in 2026, reinforcing pressure to prove that quality payments reflect real performance rather than coding or measurement artifacts. For health systems, ACOs, and payers, the strategic signal is clear: invest in scalable quality infrastructure, documentation integrity, and specialty/episode performance capabilities now, as CMS pushes more dollars through accountable models such as ACOs and TEAM while tightening the credibility of legacy quality programs ([CMS physician pay/VBC reforms](https://news.google.com/rss/articles/CBMiywFBVV95cUxNT2dHa2MyVEVua1lDYWducm1nTVBZSl8weTJ3QU16czJ1TEVqMEMxT2ZJQU4xSjdRLXo2TEVDZzhJb3F6a2pHbzlMOXUzWFlFSGRSYjMyb0ZFcWZpSWlEZmpNTzVpVnd

CMS’s WISeR Medicare prior authorization pilot has become the flashpoint for AI governance in value-based care: lawmakers are pressing CMS for more transparency, while CMS has reportedly ordered a corrective action plan for an AI vendor—signaling that automation in utilization management will face tighter scrutiny around beneficiary access, model accountability, and operational controls. At the same time, Congress is moving to reduce digital quality reporting burden for Medicare ACOs, underscoring a broader shift from “more health IT” to usable infrastructure that supports risk-based performance rather than adding compliance drag ([ACO reporting bill](https://www.ajmc.com/view/house-passes-bill-to-ease-medicare-aco-digital-quality-reporting-burden)). For health systems, ACOs, and payers, the strategic takeaway is that fragmented data and immature AI oversight are now financial and regulatory liabilities: VBC winners will need point-of-care interoperability, auditable AI workflows, and governance processes that can withstand CMS and congressional review ([missing VBC infrastructure](https://hospitalogy.com/articles/2026-06-25/the-missing-infrastructure-for-value-based-care/)).

Population health management activity is concentrating around higher-acuity, specialty and post-acute populations rather than generic primary-care attribution: HCTTF’s Strive Health case study frames value-based kidney care around earlier CKD identification, risk-aligned nephrology partnerships, multidisciplinary care teams, and total-cost accountability for CKD/ESKD patients ([HCTTF case study](https://hcttf.org/a-better-model-for-kidney-care-earlier-identification-smarter-coordination-better-outcomes/)). At the same time, ACO enablement and Medicare chronic-care infrastructure are drawing new capital and platform positioning—Pearl Health’s $110M raise and Innovaccer’s CMS ACCESS participation signal continued competition to control analytics, workflow, and care-management rails for Medicare VBC—while post-acute visibility, behavioral health integration, and oncology/cancer value models remain pressure points for organizations trying to manage longitudinal risk beyond the primary-care visit ([Pearl Health funding](https://news.google.com/rss/articles/CBMiY0FVX3lxTFBqR3ZSZWR0c1k4Ylp4aThmUW9PWW5xZWIxMEUydjdnZzdiZEpjUU8zdFNBV0VBUXdKMkx3b2F0OTB0R0tUaUtWejlUWG4tS2pRUExyUEVFdkgyZktxTldIcUZ).

Payment integrity is becoming a more explicit VBC operating constraint, with CMS scrutiny centering on Medicare Advantage coding intensity, RADV extrapolation exposure, and the validity of in-home assessment diagnoses—issues that directly affect MA revenue, risk adjustment strategy, and provider-plan alignment under value-based contracts. At the same time, CMS’s WISeR Medicare prior authorization pilot is drawing congressional pressure and vendor oversight concerns, signaling that AI-enabled utilization management will face tighter transparency and governance expectations even as the Trump administration’s CMS looks for tools to curb inappropriate spending. For ACOs and risk-bearing providers, the near-term takeaway is a widening compliance perimeter: MA payment accuracy debates, Stars litigation, and FWA/waiver management are converging into a more adversarial environment where documentation quality, audit readiness, and defensible care-management workflows are strategic necessities, not back-office functions ([KFF on MA coding intensity](https://www.kff.org/medicare/decoding-medicare-advantage-coding-intensity/); [Healthcare Dive on WISeR scrutiny](https://www.healthcaredive.com/news/democrat-letter-more-data-wiser-medicare-ai-prior-authorization/823581/)).

CMS’ new Medicaid work requirements implementation is turning health equity and SDoH strategy into an eligibility, documentation, and care-management problem for Medicaid plans, ACO-adjacent providers, and safety-net systems—especially around medical frailty exemptions, HIV, behavioral health, and other populations likely to face administrative churn. At the same time, scrutiny of CMMI’s ACCESS behavioral health model signals a broader VBC tension: policymakers are pushing integration and accountability for behavioral health and social complexity, but providers argue the model economics may not support the staffing and infrastructure required. The strategic implication is that health systems and CHCs must strengthen exemption workflows, risk adjustment documentation, community-based care partnerships, and Medicaid scenario planning as the Trump administration’s Medicaid rules and financing limits reshape the economics of population health for low-income patients ([KFF on medical frailty exemptions](https://www.kff.org/medicaid/the-medical-frailty-exemption-from-medicaid-work-requirements-key-takeaways-from-the-cms-interim-final-rule/); [Becker’s on ACCESS model scrutiny](https://www.beckersbehavioralhealth.com/payer/the-economics-just-dont-work-what-to-know-about-cms-access-model/)).

CMS drug-payment policy is pushing Medicare Advantage and Part D sponsors toward more active pharmacy-risk management: MA plans need to prepare for Part B negotiated drug prices affecting benefit design, provider contracting, and rebate/medical-loss-ratio strategy, while Part D sponsors face a compressed post-NAMBA rebate reallocation window that can materially change bids and supplemental benefits ([Avalere](https://advisory.avalerehealth.com/insights/part-b-negotiated-drug-prices-how-ma-plans-should-prepare), [Wakely](https://www.wakely.com/blog/rebate-reallocation-a-pre-namba-strategy-guide/)). At the same time, federal pharmacy demonstrations and renewed attention to outcomes-based contracts are increasing pressure on Medicaid agencies, payers, and manufacturers to link drug spend to measurable value—creating opportunities for VBC entities that can track outcomes, manage specialty-drug utilization, and align pharmacy strategy with total-cost-of-care performance.

Medicaid managed care is entering a sharper margin-and-accountability cycle: CBO’s post-2025 reconciliation projections point to materially lower federal Medicaid spending and enrollment over the decade, while plans are already reassessing market participation, with Elevance exiting D.C. Medicaid and evaluating additional withdrawals as rate adequacy and acuity pressures intensify. At the same time, CMS under the Trump administration is pushing ahead with the ACCESS behavioral health model, but provider and payer scrutiny centers on whether Medicaid payment rates, workforce constraints, and managed care incentives can support the model’s access and integration goals without worsening financial strain. For VBC stakeholders, the strategic issue is no longer just model participation; it is whether Medicaid ACOs, FQHCs, behavioral health providers, and MCOs can align risk, rates, and care-management infrastructure in a tighter fiscal environment. [KFF Medicaid projections](https://www.kff.org/medicaid/how-has-projected-medicaid-spending-and-enrollment-changed-since-passage-of-the-2025-reconciliation-law/) | [ACCESS model scrutiny](https://www.beckersbehavioralhealth.com/payer/the-economics-just-dont-work-what-to-know-about-cms-access-model/)

CMS under the Trump administration is signaling a more aggressive VBC consolidation agenda: proposed Medicare physician payment reforms would expand ACO participation, move away from MIPS, and strengthen MSSP as the default accountable-care chassis, while stakeholders are also preparing for mandatory episode-based risk under TEAM. At the same time, [ACO REACH’s reported $988M in 2024 net savings before its sunset](https://news.google.com/rss/articles/CBMimAFBVV95cUxOSmhRVVVlX1BNblBYdGlGT19SNk4ydTNBelhteHgtLV81MmVINmVvdnFSQkZxMFVFRHpLelFfRTFmM05RZkV2UF9lYlRtZVlYVHl1a3lZelRwMV9PaEF3eEFlbmU4TUdUSG9LWXY4NUN2RXAwNEpHcTBwQWdkRGNRaFZkcVE3cVZ5NzhTR1N3bWtCbVpxdEFxYg?oc=5) creates a policy tension for CMMI Director Abe Sutton’s team: how to preserve evidence-generating downside-risk models while addressing scrutiny over CMMI’s broader fiscal footprint and reporting gaps. For VBC leaders, the strategic implication is clear—capital and operating focus are shifting toward MSSP/ACO infrastructure, specialty

CMS’s July launch of the ACCESS Model is pushing primary-care-adjacent chronic disease management further into Medicare value-based payment, with digital health and enablement companies positioning around lower-margin, population-scale economics rather than visit-based revenue; the AMA’s physician-facing guidance underscores that clinicians will need to understand how these model payments intersect with existing care teams and practice workflows ([AMA on CMS ACCESS](https://news.google.com/rss/articles/CBMiwgFBVV95cUxPdm0wY1I3d0IyR1UycEIxeGZZcWtaaDdrWDZpUEVXYVlWbHhSeHF2N20zRUNkU1pkTUE2NmtuV0p3TWtnUWl6cHJOOVM4elIwckZkQ0U2OWJiWklTTDVRbDFldTNDdkRKcjV3QmpQRWxHcFJEdllxbEpwdEhIdTJROVdCVVJCSWxWbnpSQW4xUVk3Y3R6RGs1a1dESTdZSjZiUWVKcVZudnppOUE2dDdWTkpKRnk2UmlPWGdxYVlVdEE5Zw?oc=5)). At the same time, CMS’s proposed 2027 Medicare Physician Fee Schedule is being received by ACP as a constructive move for internal

CMS under the Trump administration is tightening the economics and compliance perimeter for digital care in Medicare: the proposed physician fee schedule shift to bar third-party vendors from furnishing remote patient monitoring on behalf of clinicians would materially disrupt RPM operating models, while the ACCESS chronic disease experiment appears to pay digital health vendors at Medicare-population-health rates rather than commercial point-solution prices. For VBC stakeholders, the signal is that digital health must move from outsourced utilization add-on to accountable, clinically integrated infrastructure—supported by emerging quality frameworks such as NCQA’s Digital Health Engagement Accreditation, but pressured by fraud enforcement and CMS scrutiny of vendor-led telehealth/RPM models. The strategic tension is whether ACOs, MA plans, CHCs, and health systems can absorb AI, RPM, ambient documentation, adherence sensors, and activation platforms into longitudinal care management fast enough to improve outcomes and total cost of care under lower, more regulated reimbursement assumptions ([CMS RPM proposal](https://www.statnews.com/2026/07/15/cms-proposes-ban-medicare-remote-patient-monitoring-vendors/?utm_campaign=rss); [CMS ACCESS economics](https://endpoints.news/how-digital-health-companies-are-planning-to-conquer-cms-access/)).

Medicare Advantage risk adjustment is moving from a coding-optimization growth engine to a payment-accuracy and audit-risk battleground, with CMS scrutiny of coding intensity, RADV extrapolation exposure, and MA quality-rating litigation increasing the financial stakes for plans, delegated risk groups, and VBC enablement vendors. The strategic split is widening: payers are defending in-home assessment programs such as UnitedHealth’s HouseCalls with medical-record support rates, while policy analysts and actuaries focus on whether MA diagnoses are generating excess federal payments and how repayment risk should be modeled under RADV extrapolation ([KFF coding intensity brief](https://www.kff.org/medicare/decoding-medicare-advantage-coding-intensity/); [Wakely RADV guide](https://www.wakely.com/blog/medicare-advantage-radv-extrapolation-a-practical-guide-for-plans/)). For ACOs, health systems, and population-health platforms, the implication is that risk capture must be redesigned around clinically supported documentation, longitudinal data integration, and point-of-care workflows—not retrospective chart chasing—because fragmented patient data is becoming both a revenue leakage problem and a compliance liability in value-based contracts.

Medicare Advantage Star Ratings have shifted from a quality-performance mechanism into a high-stakes payment and litigation battleground, as CMS faces insurer lawsuits from SCAN and Alignment seeking broader recalculation after the Clover-related methodology dispute, while the 2026 Quality Bonus Program is still projected to drive more than $13 billion in MA payments with 68% of enrollees in bonus-eligible plans ([KFF](https://www.kff.org/medicare/medicare-will-spend-more-than-13-billion-on-the-medicare-advantage-quality-bonus-program-in-2026/)). For VBC stakeholders, the strategic issue is no longer just Stars execution but revenue durability under the Trump administration’s CMS, as quality bonuses, coding intensity scrutiny, RADV repayment exposure, and documentation integrity are converging into a broader test of MA payment accuracy and plan-provider risk arrangements ([Healthcare Dive](https://www.healthcaredive.com/news/scan-alignment-sue-cms-ma-star-ratings-recalculation-clover-lawsuits/825091/)).

CMS’ latest 2024 results strengthen the case that ACO REACH is producing material Medicare savings before its scheduled year-end sunset, with the model generating $988 million in Medicare savings and participants such as agilon reporting $229 million in gross savings and $54 million to the Trust Fund. The strategic question for ACOs is shifting from “does REACH work?” to how organizations position for the next model cycle—particularly LEAD versus MSSP—as CMS under the Trump administration advances proposed physician payment and MSSP changes aimed at expanding ACO participation while stakeholders await LEAD financial methodology details and face near-term participation decisions. For VBC leaders, the core tension is whether CMS converts REACH’s demonstrated savings into a durable high-accountability pathway or pushes more organizations into MSSP-style structures with different benchmarking, risk, and operational requirements. [Healthcare Dive](https://www.healthcaredive.com/news/aco-reach-generates-more-savings-medicare/824965/) [Wakely](https://www.wakely.com/blog/accepted-into-lead-now-what-aco-risk-mitigation-strategies-part-2/)

Workforce capacity is becoming a harder operational constraint on VBC execution, with Medicaid-financed direct care workers, immigrant clinicians and aides, behavioral health staff, and primary care teams all emerging as bottlenecks for home-based care, LTSS diversion, care management, and risk-bearing population health models. Recent analyses from [KFF on direct care workers](https://www.kff.org/medicaid/who-are-direct-care-workers-and-how-might-federal-policy-changes-impact-the-workforce/) and [NASHP on state behavioral health workforce strategies](https://nashp.org/lessons-from-5-states-on-building-a-stronger-behavioral-health-workforce/) point to a widening tension for ACOs, Medicaid managed care plans, and health systems: payment models increasingly depend on upstream, team-based, community-delivered care, but the labor pipeline and wage structure remain fragile. At the same time, revenue-cycle modernization and Medicare assessment changes are keeping operational infrastructure in focus, signaling that VBC organizations will need to invest simultaneously in workforce redesign, medical management, and administrative automation to protect margins while taking on more accountability.

Bundled-payment activity is shifting from legacy orthopedic episodes toward broader, mandatory episode accountability under CMS models such as TEAM and the proposed/related CJR-X framework, forcing hospitals to build stronger governance, CDI/coding, utilization review, post-discharge management, and physician-alignment infrastructure rather than treating bundles as isolated finance projects. Health systems are already positioning operationally—e.g., UCHealth’s partnership with Avant-garde Health to strengthen surgical performance under [CMS TEAM](https://news.google.com/rss/articles/CBMi4gFBVV95cUxOZk1lT1d6dmlTbzdkRnF6a0dWY1lQejRjSFBPQVQ3MjdLN2ZEMVQ4cTh2cDd4Vnp6S3ZqbGtKVllEVGh5RVhBalRhYzZVTjN3Z3lwSnN1Z0FSSk9FaF9MMHVOMm1DeFVYa0x6T3VQMTkzRVFtWWVZeGV1dkV1Zm92YVZNZlBMdEllT3h0LV9veGxiUGhQNkNGQzJsaHEyRDdvTUFLczJOLXVfbTZjX2d1QTJXSFR0Y3R4RnVDYjIzdmZDQ3A4c0huUERwX1

Behavioral health integration is moving from a clinical-access priority into a core VBC infrastructure issue, with Medicaid managed care contracts increasingly using care coordination requirements, quality measures, and payment levers to embed behavioral health into whole-person accountability ([NASHP](https://nashp.org/snapshot-behavioral-health-integration-in-medicaid-managed-care/)). At the same time, VBC stakeholders face a tightening policy and oversight environment: states are strengthening primary care-to-SUD referral pathways while also scrutinizing Medicaid behavioral health enrollment and fraud risk, creating tension between expanding access and protecting program integrity. For ACOs, Medicaid plans, and health systems, the strategic implication is clear: behavioral health capability—HEDIS performance, referral closure, crisis/SUD network connectivity, and fraud-resilient documentation—will increasingly determine success in population health contracts and risk-based models.